Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer

Oncology

Volumn 78, Issue 3-4, 2010, Pages 213-219

  Ishitobi, Makoto ^a   Komoike, Yoshifumi ^a   Motomura, Kazuyoshi ^a   Koyama, Hiroki ^a   Inaji, Hideo ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Neutropenia; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; ANTHRACYCLINES; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEUTROPENIA; PROGNOSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 77951242562     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313702     Document Type: Article

References (28)

1. Perez-Soler R, Saltz L: Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 5235-5246.
2. Cohen EE: Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2659-2665.
3. Jonker DJ, OCallaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
4. van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
5. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-smallcell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
6. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I: Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997; 75: 301-305.
7. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C: Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999; 80: 1763-1766.
8. Cameron DA, Massie C, Kerr G, Leonard RC: Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003; 89: 1837-1842.
9. Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J: Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 2008; 26: 806-813.
10. le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): an improved score modification based on a multivariate analysis of 1,262 invasive ductal breast carcinomas. Cancer 1989; 64: 1914-1921.
11. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK: Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007; 17:CD004421.
12. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10-15.
13. Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators: Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100: 805-814.
14. di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, Manzione L, Illiano A, Barbera S, Robbiati SF, Frontini L, Piazza E, Ianniello GP, Veltri E, Castiglione F, Rosetti F, Gebbia V, Seymour L, Chiodini P, Perrone F: Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005; 6: 669-677.
15. Shitara K, Matsuo K, Takahari D, Yokota T, Inaba Y, Yamaura H, Sato Y, Najima M, Ura T, Muro K: Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer 2009; 45: 1757-1763.
16. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M: Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 2007; 97: 37-42.
17. Gurney H: Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14: 2590-2611.
18. Gurney H: How to calculate the dose of chemotherapy. Br J Cancer 2002; 86: 1297-1302.
19. Ishitobi M, Komoike Y, Motomura K, Koyama H, Inaji H: Early response to neoadjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence. Breast J 2009, Epub ahead of print.
20. Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE: Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006; 239: 361-374.
21. Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY: MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 2008; 112: 17-26.
22. Martincich L, Montemurro F, de Rosa G, Marra V, Ponzone R, Cirillo S, Gatti M, Bi glia N, Sarotto I, Sismondi P, Regge D, Aglietta M: Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004; 83: 67-76.
23. Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, Stirling JJ, D'Arcy JA, Collins DJ, Pittam MR, Ravichandran D, Padhani AR: Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008; 14: 6580-6589.
24. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF, Campone M: Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [ 18 F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006; 24: 5366-5372.
25. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N: Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785.
26. Dees EC, O'Reilly S, Goodman SN, Sartorius S, Levine MA, Jones RJ, Grochow LB, Donehower RC, Fetting JH: A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000; 18: 521-529.
27. Crawford J, Dale DC, Lyman GH: Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228-237.
28. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokum-pu-Lehtinen P, Bengtsson N, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384-1391.